SRTA(SRTA)
SRTA
10/7/26
Strata Critical Medical (SRTA)
Wednesday
1:24 PM
ThesisThe recent strategic partnerships and advancements in technology are expected to significantly enhance SRTA's market position and revenue potential.
Revenue Outlook
Why Revenue Could Explode
- 01SRTA's recent partnership with a major hospital network could increase patient transport volume by 25%.
- 02Introduction of a next-generation medical device that reduces transport time by 15%, enhancing competitive positioning.
- 03Potential regulatory changes that could expand the market for air medical transport services by 30%.
- 04A recent study showing improved patient outcomes with SRTA's devices could drive demand and increase sales by 20%.
- 05Growth in telehealth and emergency medical services
- 06Increased focus on patient outcomes in critical care
- 07Changes in air medical transport regulations
- 08Advancements in medical technology impacting device sales
FY2025 Snapshot
- Revenue
- $197M
- Rev. Growth
- -20.7%
- Gross Margin
- 20.9%
- Op. Margin
- -11.3%
- Net Margin
- 21.0%
- Net Income
- $41M
- NI Growth
- +251%
- EPS
- $0.50
- 1Y Return
- -10.1%
SRTA Chart
My Notes
- "We are poised for growth as we expand our partnerships and innovate our product offerings."
- Moat: SRTA's proprietary technology provides a strong competitive advantage, but it must continuously innovate to maintain this edge.
- growth - Investors may be drawn to SRTA due to its potential for high revenue growth in a niche market.
- Interest rates can affect SRTA's financing costs for equipment and fleet maintenance, impacting profitability and capital expenditures.
- Watch on earnings: Regulatory changes affecting air medical transport, Market share in the air ambulance sector, Sales growth of medical devices.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $291M to $326M as srta's recent partnership with a major hospital network could increase patient transport volume by 25%.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Strategy Focus List
Continuous multi-factor scoring & catalyst forensics
Market Movers
Today's biggest gainers and losers